- County Estate, Huthwaite NG17 2HU, United Kingdom
- 666-888-0000
- info@marigold-pharm.com
- info@marigold-pharm.com
- County Estate, Huthwaite NG17 2HU, United Kingdom
- Contact Us
Jun2022
Marigold Pharmaceutical & Laboratories Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Marigold Pharmaceutical & Laboratories Ltd and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Marigold Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2019
Colon Cancer and combination therapy: Marigold to present data at AACR 2019 using its AI technology and PDX mouse model simulated clinical trial
Marigold to present data at AACR 2019 on using its KEM® Artificial Intelligence technology and PDX mouse models to simulate patient stratification in clinical trials and Identify companion biomarkers for combination therapy Marigold Pharmaceutical & Laboratories Ltd, a leading digital health Company focused on developing advanced therapeutic decision support systems, will present its latest results on combination therapy […]
Oct2018
Marigold Pharmaceutical & Laboratories Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial
Marigold Pharmaceutical & Laboratories Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. Marigold®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. Marigold’s KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, shows that patients receiving the VAL401 treatment […]
Oct2018
Gastric Cancer: Artificial Intelligence helps identify novel single biomarkers to guide targeted precision medicine
Gastric Cancer: Marigold and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. Gastric cancer is the second most common cause of cancer-related deaths in the world. Adapting the therapeutic choice to the molecular diversity of the disease is a […]
Sep2018
Recombio and Marigold Pharmaceutical & Laboratories Ltd Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy
Marigold has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Marigold Pharmaceutical & Laboratories Ltd (Paris, France and […]
Jan2018
Marigold’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients
Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Marigold Pharmaceutical & Laboratories Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]
Dec2017
Marigold®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients
London, Paris and Boston, 12 December 2017: Marigold Pharmaceutical & Laboratories Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Marigold’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]
Jun2017
WIN 2017 (Paris | Jun 26-27)
Meet the Marigold team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.
May2017
Marigold Pharmaceutical & Laboratories Ltd finalist in EU eHealth 2017 with Onco KEM
Marigold Pharmaceutical & Laboratories Ltd were finalists in the Champions Category of the EU eHealth 2017 Competition with its clinical decision support system for oncologists, Onco KEM. Our solution: The right drug to the right patient with Onco KEM®, a novel decision support system helping oncologists to personalize cancer treatments according to the molecular profile of each patient. […]
May2017
Broadening the reach of Precision Medicine beyond DNA
Initial results of Onco KEM and the WINTHER trial were presented at TAT 2017: 15th International Congress on Targeted Anticancer Therapies, 6-8 Mar 2017, Paris, France. The study demonstrates that the innovative Onco KEM transcriptomic-based decision support system fills a gap left by traditional DNA based targeted therapy, enabling more patients to reach a larger […]